Ultimate Assessment Program 2027/28/29 || 1:1 Mentorship Batch Admissions Open

Why in the News

Reports of fake cancer drugs seized from a licensed distributor in Karnataka have revived alarm about counterfeit medicines, but the State has not confirmed them. Counterfeiting is a minor problem in India, and the real gaps lie in how drugs are transported and stored.

How big is India’s counterfeit drug problem?

  1. What it is: A counterfeit drug is a fake passed off as genuine, like a fake branded watch. A substandard drug is genuine but fails quality tests, like a real watch that runs slow.
  2. Survey finding: The last National Drug Survey, published in 2017, found counterfeits at a negligible 0.0245% of the market, through routine sampling by drug inspectors.
  3. Where counterfeiters go: Skilled counterfeiters prefer cosmetics and fast-moving consumer goods (FMCG), where legal risk is lower and fakes slip more easily into supply chains.
  4. Paper trail: Pharmacies and distributors record every purchase, since the records let them claim immunity under Section 19(3) of the Drugs and Cosmetics Act, 1940. The immunity protects sellers who bought in good faith from licensed sources.
  5. The takeaway: The drug trade’s record keeping makes fakes risky to sell, which is why counterfeiting stays rare.

Why does counterfeiting draw more alarm than the data justify?

  1. Unconfirmed seizure: The Government of Karnataka has not confirmed that counterfeit cancer drugs were seized. A purported list of seized drugs on social media showed only antibiotics.
  2. Costly silence: Karnataka’s Health Department has stayed silent, so cancer patients fear their medicines were fake and bereaved families are left in doubt.
  3. Emotive coverage: Fake cancer drugs are a sensational issue that provokes demands for severe action, even death sentences for distributors.
  4. The 25% myth: An unfounded 25% share of fake drugs, attributed to the World Health Organization (WHO), circulated in the press for years and scared policymakers before disappearing.
  5. Technology lobby: Firms selling anti-counterfeiting technology press the Union government to make it a legal standard for all drug makers. Some file disguised Public Interest Litigation (PIL), petitions framed as public causes, to push it.

What would mandates cost, and where are the real gaps?

  1. Costlier medicines: Drug companies would pass the cost of mandated technologies on to patients, so medicines would become more expensive.
  2. Proportionate response: Policy should match the small size of the problem and keep drug prices low, so the Ministry of Health should resist this lobbying.
  3. Transport loophole: No licensing framework covers those who carry drugs between manufacturers and distributors or retailers. The Supreme Court first raised this in the 1970s, and it remains unaddressed.
  4. Stalled distribution norms: The WHO’s Good Distribution Practices, rules for storing and moving drugs, have awaited the Health Minister’s approval for more than a decade.

Challenges

  1. Too few inspectors: State drug control departments lack enough inspectors to sample a vast network of makers and sellers.
  2. Substandard over fake: Quality failures in genuine drugs pose a larger risk than counterfeits. Eg. Indian-made cough syrups linked to child deaths in Gambia, 2022.
  3. Stale evidence: National prevalence data are almost a decade old, so policy rests on old numbers.

Way Forward

  1. Clear the air: Karnataka’s Health Department should name any seized drugs and the hospitals affected, or state publicly that none were found.
  2. License transporters: Bring drug transporters under licensing through the Drugs and Cosmetics Rules, 1945.
  3. Notify distribution standards: The Union Health Ministry should adopt the pending Good Distribution Practices for storage and transport.
  4. Fresh survey: Commission a new National Drug Survey to update prevalence data.
  5. Price test for mandates: Weigh any anti-counterfeiting technology against its effect on what patients pay.

Conclusion

India’s weak point in drug safety lies less in counterfeit medicines than in an unregulated supply chain between factory and pharmacy. Whether the Health Ministry licenses transporters and notifies distribution standards, rather than adopting costly technology mandates, is what to watch.

Drug regulation in India

  1. Constitutional basis: Drugs and poisons sit in Entry 19 of the Concurrent List, so both the Centre and the States can legislate on them.
  2. Central regulator: The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), oversees quality, safety and new drug approvals.
  3. State licensing: State drug controllers license the manufacture and sale of most drugs, and their inspectors sample drugs.
  4. Split control: The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, controls prices; quality sits with the Health Ministry.

Matching Previous Year Question

“No direct PYQ traced in the provided files. Thematic PYQ: [2024, GS2, 15 marks] In a crucial domain like the public healthcare system, the Indian State should play a vital role to contain the adverse impact of marketisation of the system. Suggest some measures through which the State can enhance the reach of public healthcare at the grassroots level.”

Click here to Download X-Factor Notes for FREE. Cover the entire Microthemes with PYQs.

Download free X-Factor Notes
Revised and updated X-Factor Notes for UPSC Mains 2026: nine subject booklets